Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Exicure stock
Own Exicure stock in just a few minutes.
Exicure, Inc is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 63 staff and has a trailing 12-month revenue of around USD$16.6 million.
How to buy shares in Exicure
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Exicure. Find the stock by name or ticker symbol: XCUR. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Exicure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Exicure, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Exicure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Exicure share price
Use our graph to track the performance of XCUR stocks over time.Exicure shares at a glance
Information last updated 2021-04-09.
| 52-week range | USD$1.38 - USD$3.19 |
|---|---|
| 50-day moving average | USD$2.2725 |
| 200-day moving average | USD$1.97 |
| Wall St. target price | USD$10 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.471 |
Buy Exicure shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Exicure stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exicure financials
| Revenue TTM | USD$16.6 million |
|---|---|
| Gross profit TTM | USD$-15,481,000 |
| Return on assets TTM | -14.74% |
| Return on equity TTM | -34.68% |
| Profit margin | -148.49% |
| Book value | $0.702 |
| Market capitalisation | USD$186.5 million |
TTM: trailing 12 months
Shorting Exicure shares
There are currently 1.5 million Exicure shares held short by investors – that's known as Exicure's "short interest". This figure is 13.2% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Exicure shares can be evaluated.
Exicure's "short interest ratio" (SIR)
Exicure's "short interest ratio" (SIR) is the quantity of Exicure shares currently shorted divided by the average quantity of Exicure shares traded daily (recently around 680935.84070796). Exicure's SIR currently stands at 2.26. In other words for every 100,000 Exicure shares traded daily on the market, roughly 2260 shares are currently held short.
However Exicure's short interest can also be evaluated against the total number of Exicure shares, or, against the total number of tradable Exicure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exicure's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Exicure shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Exicure shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exicure.
Find out more about how you can short Exicure stock.
Exicure share dividends
We're not expecting Exicure to pay a dividend over the next 12 months.
Exicure share price volatility
Over the last 12 months, Exicure's shares have ranged in value from as little as $1.38 up to $3.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.3704. This would suggest that Exicure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Exicure overview
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Frequently asked questions
More guides on Finder
-
How to buy PrimeEnergy Resources Corporation stock
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
-
How to buy Premier stock
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
-
How to buy Predictive Oncology stock
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
-
How to buy Powerbridge Technologies CoLtd stock
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
-
How to buy Portman Ridge Finance Corporation stock
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
-
How to buy Popular stock
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
-
How to buy Playa Hotels-and-Resorts N-V stock
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
-
How to buy Plains GP Holdings L-P stock
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
-
How to buy Plains All American Pipeline L-P stock
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
-
How to buy Property Solutions Acquisition stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Ask an Expert